Expertise in
18
conditions

Dr. Hassan Alkhateeb

Hematology | Oncology
Mayo Clinic Bone Marrow Transplant Program
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
18
conditions
Mayo Clinic Bone Marrow Transplant Program
200 1st St Sw, 
Rochester, MN 

Overview

Hassan Alkhateeb is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. He has been practicing medicine for over 18 years.

Dr. Alkhateeb is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 201 peer reviewed articles and participating in 5 clinical trials. Dr. Alkhateeb is currently accepting new patients.

Graduate Year

2008

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Health System-Franciscan Medical Center Inc
Mayo Clinic Health System - Albert Lea And Austin
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Itasca Medical Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Mayo Clinic Bone Marrow Transplant Program
200 1st St Sw, Rochester, MN 55905
Other Locations
MN - Cancer Hematology
200 1st St SW, Rochester, MN 55905

Additional Areas of Focus

Dr. Alkhateeb has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug, Procedure
Study Drugs: Venetoclax, Liposomal Vincristine
Study Phase: Phase 1/Phase 2
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Enrollment Status: Terminated
Publish Date: January 12, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2/Phase 3
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drugs: Insulin-Like Growth Factor, Methotrexate
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

201 Total Publications

Unique Aspects of Allogeneic Hematopoietic Stem Cell Transplantation in VEXAS Syndrome: One Size Does Not Fit All.
Unique Aspects of Allogeneic Hematopoietic Stem Cell Transplantation in VEXAS Syndrome: One Size Does Not Fit All.
Journal: American journal of hematology
Published: July 18, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Ansell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-512-1667
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Go is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Rosai-Dorfman Disease, Histiocytosis, Reticulohistiocytoma, Bone Marrow Transplant, and Splenectomy. Dr. Go is currently accepting new patients.

Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Buadi is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Buadi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, POEMS Syndrome, and Bone Marrow Transplant. Dr. Buadi is currently accepting new patients.

Frequently Asked Questions about Dr. Hassan Alkhateeb

How do I make an appointment with Dr. Hassan Alkhateeb?

You can book an appointment with Dr. Hassan Alkhateeb by calling their office at 507-229-0068. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hassan Alkhateeb a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hassan Alkhateeb is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hassan Alkhateeb specialize in?

While Dr. Hassan Alkhateeb is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Hassan Alkhateeb participate in research or clinical trials?

Yes. Dr. Hassan Alkhateeb has published 201 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Hassan Alkhateeb's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Hassan Alkhateeb accept my insurance?

Dr. Hassan Alkhateeb accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 507-229-0068 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alkhateeb's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile